Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference [Yahoo! Finance]
Context Therapeutics Inc. (CNTX)
Company Research
Source: Yahoo! Finance
and plans to enter the clinic with Nectin-4 (CT-202) the same quarter, while mesothelin (CT-95) data are targeted for mid-2026 to create an "almost quarterly" update cadence. Promising program features: Early Claudin-6 data include a deep, durable confirmed response in an ADC-experienced ovarian patient and ~500-fold preclinical selectivity versus Claudin-3/4; CT-95 is engineered with ~40-fold lower mesothelin affinity to improve safety, and CT-202 uses pH-dependent binders with completed GLP toxicology showing reduced skin binding and favorable preclinical tolerability. Financing and runway: Context raised $115 million in 2025 and says it is well-financed with cash expected to fund operations through these near-term clinical inflection points. Interested in Context Therapeutics Inc.? Here are five stocks we like better. Context Therapeutics (NASDAQ:CNTX) CEO Martin Lehr outlined the company's strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Con
Show less
Read more
Impact Snapshot
Event Time:
CNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTX alerts
High impacting Context Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CNTX
News
- Context Therapeutics (CNTX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $9.00 price target on the stock.MarketBeat
- Context Therapeutics (CNTX) had its "buy" rating reaffirmed by Guggenheim. They now have a $5.00 price target on the stock.MarketBeat
- Context Therapeutics (CNTX) had its price target raised by Piper Sandler from $4.00 to $7.00. They now have an "overweight" rating on the stock.MarketBeat
- Context Therapeutics Reports Full Year 2025 Operating and Financial Results [Yahoo! Finance]Yahoo! Finance
- Context Therapeutics GAAP EPS of -$0.38 [Seeking Alpha]Seeking Alpha
CNTX
Sec Filings
- 3/23/26 - Form S-8
- 3/23/26 - Form 8-K
- 3/23/26 - Form 10-K
- CNTX's page on the SEC website